223 related articles for article (PubMed ID: 31188129)
21. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
Castells MC; Tennant NM; Sloane DE; Hsu FI; Barrett NA; Hong DI; Laidlaw TM; Legere HJ; Nallamshetty SN; Palis RI; Rao JJ; Berlin ST; Campos SM; Matulonis UA
J Allergy Clin Immunol; 2008 Sep; 122(3):574-80. PubMed ID: 18502492
[TBL] [Abstract][Full Text] [Related]
22. Oxaliplatin hypersensitivity complicated by thrombocytopenia during desensitization.
Tuttle KL; Stavrou E; Hong DIC; Connell NT; Wickner P
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):267-269. PubMed ID: 33971363
[No Abstract] [Full Text] [Related]
23. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.
Vyskocil J; Tucek S; Kiss I; Fedorova L; Nevrlka J; Zdrazilova-Dubska L
Int Immunopharmacol; 2019 Sep; 74():105728. PubMed ID: 31288153
[TBL] [Abstract][Full Text] [Related]
24. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule.
Meyer L; Zuberbier T; Worm M; Oettle H; Riess H
J Clin Oncol; 2002 Feb; 20(4):1146-7. PubMed ID: 11844841
[No Abstract] [Full Text] [Related]
25. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.
Gammon D; Bhargava P; McCormick MJ
Oncologist; 2004; 9(5):546-9. PubMed ID: 15477639
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of rapid drug desensitization in children.
Esenboga S; Akarsu A; Ocak M; Gur Cetinkaya P; Sahiner UM; Sekerel BE; Soyer O
Pediatr Allergy Immunol; 2022 Mar; 33(3):e13759. PubMed ID: 35338724
[TBL] [Abstract][Full Text] [Related]
27. Basophil Activation Test is a Relevant Biomarker of the Outcome of Rapid Desensitization in Platinum Compounds-Allergy.
Giavina-Bianchi P; Galvão VR; Picard M; Caiado J; Castells MC
J Allergy Clin Immunol Pract; 2017; 5(3):728-736. PubMed ID: 28034549
[TBL] [Abstract][Full Text] [Related]
28. Hypersensitivity reactions to anticancer chemotherapy and monoclonal antibodies: Safety and efficacy of desensitization.
Villarreal-González RV; González-Díaz S; Vidal-Gutiérrez O; Cruz-de la Cruz C; Pérez-Ibave DC; Garza-Rodríguez ML
J Oncol Pharm Pract; 2024 Jul; 30(5):811-822. PubMed ID: 37489025
[TBL] [Abstract][Full Text] [Related]
29. Platinum Chemotherapy Hypersensitivity: Prevalence and Management.
Otani IM; Wong J; Banerji A
Immunol Allergy Clin North Am; 2017 Nov; 37(4):663-677. PubMed ID: 28965633
[TBL] [Abstract][Full Text] [Related]
30. One-Dilution Rapid Desensitization Protocol to Chemotherapeutic and Biological Agents: A Five-Year Experience.
Sala-Cunill A; Molina-Molina GJ; Verdesoto JT; Labrador-Horrillo M; Luengo O; Galvan-Blasco P; Guilarte M; Cardona V
J Allergy Clin Immunol Pract; 2021 Nov; 9(11):4045-4054. PubMed ID: 34214705
[TBL] [Abstract][Full Text] [Related]
31. Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France.
Botsen D; Lepoix E; Mazza C; Brasseur M; Grange A; Slimano F; Bouché O
Support Care Cancer; 2019 Sep; 27(9):3179-3182. PubMed ID: 31102054
[TBL] [Abstract][Full Text] [Related]
32. Successful desensitization with chemotherapeutic drugs: a tertiary care center experience.
Çakmak ME; Kaya SB; Can Bostan Ö; Öztürk Aktaş Ö; Damadoğlu E; Karakaya G; Kalyoncu AF
Eur Ann Allergy Clin Immunol; 2022 Mar; 54(2):90-94. PubMed ID: 33944541
[No Abstract] [Full Text] [Related]
33. Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics.
Bavbek S; Kendirlinan R; Çerçi P; Altıner S; Soyyiğit Ş; Çelebi Sözener Z; Aydın Ö; Gümüşburun R
Int Arch Allergy Immunol; 2016; 171(3-4):227-233. PubMed ID: 28049204
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin.
Herrero T; Tornero P; Infante S; Fuentes V; Sánchez MN; De Barrio M; Baeza ML
J Investig Allergol Clin Immunol; 2006; 16(5):327-30. PubMed ID: 17039675
[TBL] [Abstract][Full Text] [Related]
35. Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol.
Pérez-Rodríguez E; Martínez-Tadeo JA; Pérez-Rodríguez N; Hernández-Santana G; Callero-Viera A; Rodríguez-Plata E; García-Robaina JC
J Allergy Clin Immunol Pract; 2018; 6(5):1621-1627.e6. PubMed ID: 29361511
[TBL] [Abstract][Full Text] [Related]
36. Rechallenges without desensitization following platinum-based chemotherapy reactions.
Young FD; Aung S; Tang M; Anstey KM; Lee MC; Alfaro E; Cinar P; Ho H; Otani IM
J Oncol Pharm Pract; 2024 Apr; 30(3):572-575. PubMed ID: 38347725
[TBL] [Abstract][Full Text] [Related]
37. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy.
Wang AL; Patil SU; Long AA; Banerji A
Ann Allergy Asthma Immunol; 2015 Nov; 115(5):422-8. PubMed ID: 26298407
[TBL] [Abstract][Full Text] [Related]
38. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
Nozawa H; Muto Y; Yamada Y
Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
[TBL] [Abstract][Full Text] [Related]
39. Skin testing and desensitization outcomes among platinum-sensitive oncology patients.
Mawhirt SL; Fonacier LS; Calixte R; Davis-Lorton M; Aquino MR
Ann Allergy Asthma Immunol; 2018 Apr; 120(4):437-439. PubMed ID: 29625667
[No Abstract] [Full Text] [Related]
40. Endophenotyping Oxaliplatin Hypersensitivity: Personalizing Desensitization to the Atypical Platin.
Silver J; Garcia-Neuer M; Lynch DM; Pasaoglu G; Sloane DE; Castells M
J Allergy Clin Immunol Pract; 2020 May; 8(5):1668-1680.e2. PubMed ID: 32112926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
